GPT and metabolic dysfunction-associated steatotic liver disease: Furthermore, even though telmisartan has been shown to improve NAS and fibrosis scores in patients with MAS [117], a recent meta-analysis from Li et al. failed to prove a statistically significant decrease in serum ALT levels (although demonstrating a decreasing trend) with neither improvement in fibrosis nor NAFLD scores with ARB therapy [118].